Nivolumab for treating advanced (unresectable or metastatic) melanoma

  • Technology appraisal guidance
  • TA384
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Southampton Health Technology Assessments Centre (SHTAC):

  • Cooper K, Kalita N, Streit E, et al. Nivolumab for treating advanced (unresectable or metastatic) melanoma: A Single Technology Appraisal. Southampton Health Technology Assessments Centre (SHTAC), October 2015.

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope. Organisations listed in I were also invited to make written submissions. Organisations listed in II gave their expert views on nivolumab by making a submission to the Committee. Organisations listed in I, II and III have the opportunity to appeal against the final appraisal determination.

I. Company

  • Bristol‑Myers Squibb (nivolumab)

II. Professional/expert and patient/carer groups:

  • British Association of Dermatologists

  • British Association of Skin Cancer Specialist Nurses (BASCSN)

  • Cancer Research UK

  • Melanoma Focus

  • Melanoma UK

  • Royal College of Nursing

  • Royal College of Physicians

  • UK Clinical Pharmacy Association

  • UK Oncology Nursing Society

III. Other consultees:

  • Department of Health

  • NHS England

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Roche Products (vemurafenib)

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on nivolumab by providing oral evidence to the Committee.

  • Dr Christine Parkinson, Consultant in Medical Oncology, nominated by organisation representing Melanoma Focus – clinical expert

  • Dr Louise Fearfield, Consultant Dermatologist, nominated by organisation representing British Association of Dermatologists (BAD) – clinical expert

  • Mrs Gillian Nuttall, nominated by organisation representing Melanoma UK – patient expert

D. Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Bristol‑Myers Squibb

ISBN: 978-1-4731-1712-9